Rituximab inhibits Kv1.3 channels in human B lymphoma cells via activation of FcγRIIB receptors

► Both FcγRIIB receptor and Kv1.3 channel are expressed in malignant Daudi B cells. ► Compared to normal lymphocytes, Kv1.3 channel is highly expressed in Daudi cells. ► Kv1.3 channel in Daudi cells does not inactivate completely as normal lymphocytes. ► Rituximab inhibits Kv1.3 channel by promoting its inactivation via FcγRIIB receptor. ► Rituximab reduces membrane potential and induces apoptosis via FcγRIIB receptor.